Lexaria Bioscience Corp (CNSX:LXX)

Lexaria Bioscience Corp (CNSX:LXX)


Share Price
$ 0.99
Change
-0.07 (-6.60 %)
Market Cap
$77.85 m
Proactive Investors - Run By Investors For Investors

Lexaria Bioscience Corp

Lexaria Bioscience Corp. (CSE:LXX; OTCBB:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i.e. fat soluble) and...

EPIC: LXX
Market: CSE:LXX
OTCQX:LXRP
52-week High/Low: C$2.90 / C$0.98
Sector: Cannabis
Market Cap: $77.85 m
Website: www.lexariabioscience.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Lexaria Bioscience Corp


Lexaria Bioscience Corp Snapshot

Lexaria Bioscience Corp. (“Lexaria”) acquired the precursor to the DehydraTECH™ technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree. Lexaria has emerged as a global leader in enhancing the speed of action, flavor and gastro-intestinal delivery of orally-administered products

The Lexaria family of companies has also demonstrated early-stage effectiveness in improvements of delivery through human skin for the potential development of topically-administered products, including patches, cremes and lotions.

In 2018, Lexaria created four different wholly-owned subsidiary companies to each focus on commercial opportunities in their respective industries: Nicotine; Pharmaceuticals; Hemp; and Other. Together, they are empowered with global exclusive licenses to utilize and sub-license DehydraTECH worldwide for the delivery of molecules within their respective industries.

Lexaria has conducted ground-breaking studies to open doors previously closed to disruptive new delivery technology, including the possibility of potent and fast acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking. And, because of the demonstrated improvements in delivery, DehydraTECH also opens the possibility of utilizing micro doses in accordance with evolving FDA policies related to reducing delivered quantities of substances like nicotine.

In 2018, Lexaria demonstrated in animal studies a propensity for the DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain-barrier, initiating additional new patent applications.

Lexaria produces industry-leading research to support its novel delivery methods. Lexaria’s business model depends on industry partners who license its technology for additional R&D and consumer product development.

None of this can happen without the talented and dedicated people who have supported Lexaria’s development and growth. Lexaria’s internal and consulting team includes industry leaders, research scientists, clinicians, analytical chemists, medical schools and universities, intellectual property experts  and partnering company collaborators.

Lexaria has developed and commercialized a patented and cost-effective delivery technology (DehydraTECH™) that has been both laboratory and market proven to enhance the performance of beneficial compounds in ingestible products across four categories:

  • Taste
  • Smell
  • Speed of action
  • Bioabsorption & bioavailability

Lexaria’s technology is easily applied through incorporation of an intermediate step in the formulation and manufacturing of existing or new ingestible products.  This step involves mixing the beneficial compound of interest as a delivery “payload” together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to conjugate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into production.

Mr. Chris Bunka

Chairman of the Board & CEO

Chris has been Chairman of the Board and CEO since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience.

Chris is a serial entrepreneur and has been involved in several private and public companies since the late 1980’s. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on some of Lexaria’s pending patents.

Mr. John Docherty

President and Director
John became President of Lexaria in the Spring of 2015 and joined its board of directors a year later. Mr. Docherty was former President and Chief Operating officer of Helix BioPharma Corp. (TSX: HBP), where he led the company’s pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.

Mr. Docherty is a senior operations and management executive with over 20 years of experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies, as well as emerging private and publicly-traded start-ups.  At Helix, Mr. Docherty was also instrumental in the areas of investor and stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its board of directors. Prior to this, Mr. Docherty was president and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for use with a range of active compounds.

Mr. Docherty has also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PriceWaterhouseCoopers’ former global pharmaceutical industry consulting practice.  He is a named inventor on issued and pending patents and he has a M.Sc. in Pharmacology and a B.Sc. in Toxicology from the University of Toronto.

Dr. Edward Ergenzinger

Chief Legal Advisor and Senior Advisor of Innovation
Dr. Ergenzinger serves as an outside patent counsel to Lexaria. He is a U.S. licensed patent attorney who also holds a doctorate in Neuroscience (with concentrations in Pharmacology and Physiology). Dr. Ergenzinger has over 15 years of experience providing patent services to clients that have ranged from small start-ups to some of the world’s largest pharmaceutical and biotechnology companies. His professional experience includes serving as Director of Intellectual Property and Legal Affairs at the Duke Human Vaccine Institute, where he managed intellectual property assets arising from over $50 million dollars per year of extramural grants. He also provided seminal patent prosecution and worldwide portfolio management services for a second-generation vaccine that has been the world’s best-selling vaccine since 2010, with annual sales of up to $6.24 billion. He is lead author or co-author on over forty scientific and legal publications.

 

#100-740 McCurdy Rd
Kelowna, BC
V1X2P7
Phone:  250-765-6424

Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use